AccurEdit’s ART002 Becomes First In Vivo Gene Editing Product to Reduce LDL-C in Humans
Suzhou-based gene editing specialist AccurEdit Therapeutics announced that its in vivo gene editing product, ART002,...
Beihai Biotech Licenses Beizary to Zydus Lifesciences for US Market
China-based Zhuhai Beihai Biotech Co., Ltd announced a licensing agreement with Zydus Lifesciences, granting the...
Huadong Medicine’s HDM1005 Shows Positive Results in Phase Ia/Ib Study
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced positive results from the Phase Ia/Ib study...
PolyMed Biopharma Licenses HPB-143 to Photys Therapeutics for Global Development
PolyMed Biopharma, a Hangzhou-based developer of Proteolysis Targeting Chimera (PROTAC) drugs, has entered into a...
Samsung Bioepis’ Ospomyv and Xbryk Gain FDA Approval for RANKL Inhibitor Biosimilars
South Korea-based Samsung Bioepis Co., Ltd. announced that it has received marketing approval from the...
Kexing Biopharm’s GB05 Receives FDA Approval for Pediatric RSV Infections
China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced that it has received clinical trial approval...
Sanofi’s Merilog Biosimilar Wins FDA Approval for Diabetes Treatment
The U.S. Food and Drug Administration (FDA) has approved Sanofi-Aventis’ (EPA: SAN) Merilog, a biosimilar...
Yantai Dongcheng’s Lannacheng Bio Secures RMB150m to Advance [18F] Spiritide Study
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675)’s controlling subsidiary, Yantai Lannacheng Biotechnology Co., Ltd.,...
GSK’s Penmenvy Meningococcal Vaccine Approved by FDA for Ages 10-25
UK-based multinational GSK plc (LON: GSK) announced that it has received marketing approval from the...
3SBio and Sichuan Biokin Partner to Advance Solid Tumor Treatment in China
China-based 3SBio Inc. (HKG: 1530) has announced a strategic partnership with fellow domestic firm Sichuan...
LINDIS Biotech’s Korjuny Approved by European Commission for Malignant Ascites
Germany-based LINDIS Biotech GmbH announced that it has received market approval from the European Commission...
IASO Bio’s Fucaso NDA Accepted by Hong Kong DOH for Relapsed/Refractory Multiple Myeloma
China-based IASO Bio announced that a New Drug Application (NDA) for its BCMA-targeted chimeric antigen...
Innovent Biologics’ IBI363 Receives FDA Fast-Track Designation for sqNSCLC
China-based Innovent Biologics, Inc. (HKG: 1801) announced that it has received another fast-track designation from...
Tianyi Medical Acquires Bellco’s CRRT Filter Business for EUR11.99m
Tianyi Medical (SHE: 301097), a Ningbo-based developer of Class III medical consumables, has announced plans...
Konruns Pharmaceutical’s KC1036 Enters Phase II Trial for Ewing’s Sarcoma in Adolescents
Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) announced the first patient dosing in a Phase...
Hengrui Pharma Submits Ivarmacitinib Ointment for AD Treatment Approval
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced the submission of a marketing filing for...
Deep Analysis and Strategic Insights: The Impact of Vice President Yu Bing’s Departure on BCHT Biotechnology
In a move that has sent ripples through China’s vaccine industry, Changchun BCHT Biotechnology Co.,...
Beijing Wanjie Medical Device Completes Near-Hundred Million Yuan B-Round Financing
Beijing Wanjie Medical Device Co., Ltd. recently announced the successful completion of a B-round financing...
Pharmaceutical Giants Race to Integrate DeepSeek AI for Efficiency Gains
On February 14, China’s stock market saw a significant upsurge in the AI pharmaceuticals sector,...
LinkZill Completes Multi-Million-Dollar A-Round Financing Led by ProximaVentures
Hangzhou LinkZill Technology Co., Ltd. has recently completed a multi-million-dollar A-round financing, exclusively led by...